“Neoadjuvant Denosumab Therapy Improves Symptoms in Giant Cell Tumors of Bone in 24-Week Study, No Sex Differences Except in Stromal Cells”

https://pubmed.ncbi.nlm.nih.gov/38094559

This observational study found that 24-week neoadjuvant denosumab therapy improved clinical symptoms and histological indicators in patients with giant cell tumors of the bone, with no significant difference between male and female participants, except for stromal cells.